10x Genomics Begins Commercial Shipments of Xenium Prime 5K Pan-Tissue and Pathways Panel
10x Genomics (Nasdaq: TXG) has commenced commercial shipments of its new Xenium Prime 5K Pan-Tissue and Pathways panel. This advanced panel features a 5,000-plex gene capability, significantly enhancing plex capacity while maintaining top-tier per-gene sensitivity, specificity, and spatial fidelity. It also integrates multimodal cell segmentation, offering industry-leading speed and throughput. Optimized for comprehensive profiling of cell types, states, and signaling pathways across various tissues and diseases, the Xenium Prime 5K assay allows for rapid analysis of up to 472 mm² of tissue in under six days. Customizable with up to 100 additional genes, the assay is compatible with fresh frozen and FFPE samples, providing an easy, tissue-agnostic workflow. A webinar to introduce the product is scheduled for June 25, 2024.
- Introduction of a high-plex 5,000 gene panel enhancing plex capacity by order of magnitude.
- Industry-leading speed and throughput, enabling analysis of up to 472 mm² of tissue in under six days.
- High sensitivity and specificity, integrated with advanced multimodal cell segmentation.
- Customizable with up to 100 additional genes, including various novel sequences.
- Compatible with both fresh frozen and FFPE samples, providing a flexible, tissue-agnostic workflow.
- None.
Insights
The launch of the Xenium Prime 5K Pan-Tissue and Pathways panel represents a significant technological advancement in the field of single cell and spatial biology. The panel's increased plex, which now includes 5,000 genes, greatly enhances the ability of researchers to profile cell types and states, as well as cell signaling pathways, across multiple tissue and disease types. This is particularly impressive given the panel's industry-leading speed and throughput.
The technological leap here lies in the order of magnitude increase in the number of genes that can be simultaneously examined. This means researchers can gather more comprehensive data in a shorter time frame, improving the efficiency and depth of their studies. The integration of multimodal cell segmentation is also a noteworthy advancement, as it enhances the specificity and spatial fidelity of the data, which is critical for understanding complex biological systems.
For investors, these technological improvements suggest that 10x Genomics is maintaining its competitive edge in the market. The scalability and customization options also open up new avenues for tailored research, potentially expanding their customer base. However, it is important to consider the costs associated with such advanced technology and whether the market demand can justify these investments in the long term.
From a market perspective, the release of the Xenium Prime 5K gene panel underscores 10x Genomics' commitment to innovation and maintaining its leadership position in the life sciences tools industry. The ability to analyze up to 472 mm² of tissue within six days significantly reduces turnaround times, which is a compelling value proposition for researchers who require rapid results.
The market for single cell and spatial biology tools is expanding, driven by the growing demand for more precise and comprehensive biological data. The customizable nature of the panel, with the ability to add up to 100 additional genes, including specific biomarkers and transcripts, makes it a versatile tool that can be tailored to specific research needs. This could drive higher adoption rates among academic and biopharma researchers.
However, investors should be aware of potential challenges such as the cost of adoption for new and existing customers and the competitive landscape, which includes other companies developing similar technologies. The success of this product will depend on how well it is received by the research community and its ability to deliver on the promised performance enhancements.
Analyzing the financial implications, the commercial shipment of the Xenium Prime 5K is likely to have a positive impact on 10x Genomics’ revenue streams. The continuous product innovation and frequent launches, as indicated by this being the fifth major product launch this year, can contribute to sustained revenue growth and market share expansion.
Moreover, the high performance and customizability of the panel could justify a premium pricing strategy, potentially improving gross margins. However, investors should monitor the sales performance in the upcoming quarters to assess the actual market uptake and customer response.
It is also important to consider the broader financial health of the company, including R&D expenditures and how these investments are translating into returns. Given the fast pace of innovation in this sector, maintaining a balanced approach to innovation and cost management will be important for long-term financial stability.
New 5,000-plex gene panel increases plex by an order of magnitude and delivers industry-leading speed and throughput
"It's been awesome to see the early enthusiasm for the 5K gene panel from our customers, who appreciate the product for both its high plex and its high performance," said Ben Hindson, Co-Founder and Chief Scientific Officer at 10x Genomics. "Xenium Prime 5K is an incredible product that delivers outstanding results across every metric that matters, including sensitivity, specificity and throughput. This is our fifth major product launch this year, as we continue to deliver ground-breaking innovations to help customers pursue ground-breaking discoveries."
Key features of the new high-plex Xenium Prime 5K assay include:
- Highest plex Xenium panel containing 5,000 genes for the comprehensive profiling of cell types and states and cell signaling pathways across multiple tissue and disease types.
- Excellent data quality to unlock mechanisms of disease, therapeutics and cell behavior. The Xenium Prime 5K assay is optimized for performance and paired with 10x Genomics' advanced multimodal cell segmentation, enabling high sensitivity, specificity and spatial fidelity.
- Rapid turnaround time. 10x Genomics' industry-leading throughput enables researchers to analyze up to 472 mm² of human or mouse tissue in six days or less.
- Easily customizable with up to 100 additional genes, including isoforms, exogenous sequences like gRNAs and barcodes, CAR-T transcripts, viruses and more.
- Rigorously designed and developed using single cell RNA-seq data from dozens of different organs and tissues, gene expression profiles from hundreds of cell types and a screen of more than 750,000 peer-reviewed publications to pinpoint highly cited biomarkers.
- Easy, tissue-agnostic workflow compatible with both fresh frozen and FFPE samples.
The company will host a webinar to introduce the Xenium Prime 5K Pan-Tissue and Pathways panel on June 25, 2024 at 9 a.m. Pacific Time. Interested attendees can register here.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s ("10x Genomics") product launches, performance, configuration and capabilities. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the "SEC") from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-begins-commercial-shipments-of-xenium-prime-5k-pan-tissue-and-pathways-panel-302177116.html
SOURCE 10x Genomics, Inc.
FAQ
What is the new product launched by 10x Genomics?
When did 10x Genomics start shipping the Xenium Prime 5K panel?
How many genes are included in the Xenium Prime 5K panel?
What is the throughput capability of the Xenium Prime 5K panel?
Can the Xenium Prime 5K panel be customized?
What types of samples is the Xenium Prime 5K panel compatible with?
What event is scheduled by 10x Genomics to introduce the Xenium Prime 5K panel?
What are the key features of the Xenium Prime 5K panel?
